902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL

Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B C

Toward AI-Assisted Clinical Assessment for Patients with Multiple Myeloma: Feature Selection for Large Language Models

Incidence of Infections Associated with the Use of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experie

Approval Delay in Drugs from Non-Global Company in Europe and Japan: Analysis of Novel Drugs for Hematologic Malignancies

Medical Insurance Coverage and Clinical Outcomes for Patients with Hematological Malignancies in a Rural State

Treatment Outcome Priorities of Older Adults with Newly Diagnosed Blood Cancers Elicited with Best-Worst Scaling

Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of

MRD Assessment in Patients with Newly Diagnosed Multiple Myeloma Using Tokenized Real World Data Sources

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Development of a Clinical Trial Methodology and Appraisal Curriculum for Hematology Fellows

Safety and Financial Analysis of Outpatient Hypercvad Arm a Administration for Acute Lymphoblastic Leukemia

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Universal and Equitable Access to High-Cost Drugs in Uruguay. Results of 15 Years of Treatment of Non-Hodgkin Difusse Large B Cell Lymphoma (DLBCL) wi